濟民製藥(603222.SH):與美國RTI簽署生產協議第二次修訂案 合同總金額約5.4億元
格隆匯 12 月 25日丨濟民製藥(603222.SH)公佈,公司全資子公司聚民生物科技有限公司(“聚民生物”)近日與美國Retractable Technologies, Inc. (“RTI”)簽署了《生產協議第二次修訂案》,涉及9億支安全注射針(EasyPoint)和安全注射器(VanishPoint),總金額約為5.4億元人民幣(按合同簽訂日匯率計算),合同履行期限為2021年1月至2023年6月。
該合同是30個月的日常生產活動相關合同,經測算合同總金額預計約5.4億元人民幣,佔公司2019年度經審計營業收入約70.04%,合同有效期內年均執行金額佔公司2019年度經審計營業收入約28.02% 。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.